Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog fam…
An institutional-grade, numbers-driven thesis on LLY — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Eli Lilly and Company (LLY) 69/100 with a 12-month base-case forecast of $1336.18 — +12.0% versus the current price of $1192.80. Eli Lilly and Company trades at $1192.80 in the Healthcare sector, with a market capitalisation of $1.12T. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for LLY is $1336.18, implying +12.0% versus the current price. The model's 12-month scenario range runs from $1728.22 (bear) to $1962.49 (bull), with a base case of $1784.23.
On the fundamentals, Eli Lilly and shows a P/E of 40.0, trailing revenue of $65.18B, revenue growth of +44.7% YoY, a dividend yield of 0.54%. This page also tracks LLY's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
LLY currently carries a TradersQuant composite score of 69/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $1336.18 implies +12.0% from $1192.80. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for LLY is $1336.18, about +12.0% versus the latest price of $1192.80. Consensus is based on 45 analysts.
TradersQuant's 12-month model forecast for LLY is a base case of $1784.23, ranging from $1728.22 (bear) to $1962.49 (bull), an expected return of +49.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for LLY over the next 12 months is $1784.23 in the base case (bear $1728.22, bull $1962.49), versus today's price of $1192.80. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for LLY — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates LLY's fair value at $1336.18, implying +12.0% of expected upside versus the current price.
Yes — Eli Lilly and pays a dividend yielding 0.54% (about $6.46 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
